OCU410 stands apart as a gene therapy designed to target multiple pathways associated with GA, potentially delivering long-term benefits through a single subretinal injection. Dr. Shankar Musunuri ...

Researchers found the therapy downregulated VEGF expression and improved retinal thickness in neovascular age-related macular degeneration patients.

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biotechnology company developing gene therapies for the treatment of ...

The Italian Group of Vitreoretinal Surgery (Givre) announces a new appointment with AlfaLab: experts in discussion. It is ...

Anti-VEGF drugs provide anatomical control over exudation, effectively reducing subretinal and intraretinal fluid. Administered through intravitreal injection, anti-VEGF drugs need to be ...